EU routes to market for drugs and biologics
Classification decides the base. A medicinal product appearing in the Annex to Regulation (EC) No 726/2004 may be placed on the Union market only under a marketing authorisation granted by the Union in accordance with that Regulation.1 A product outside that Annex may be authorised by a national competent authority under Directive 2001/83/EC, and the mutual recognition and decentralised procedures in Article 28 of the Directive carry that authorisation into further Member States.2 Some products outside the Annex may still enter the centralised procedure by choice, on the grounds set out in Article 3(2) of the Regulation.1
The two authorisation bases
Article 6(1) of Directive 2001/83/EC provides that no medicinal product may be placed on the market of a Member State unless the competent authority of that Member State has issued an authorisation under the Directive or an authorisation has been granted under Regulation (EC) No 726/2004 read with Regulation (EC) No 1901/2006 and Regulation (EC) No 1394/2007.2 The same requirement applies to radionuclide generators, kits, radionuclide precursor radiopharmaceuticals and industrially prepared radiopharmaceuticals.2
Once an initial authorisation exists, any additional strength, pharmaceutical form, route of administration or presentation must also be authorised on one of those bases or included in the initial authorisation. Variations and extensions are handled the same way. All of these authorisations form a single global marketing authorisation, which matters in particular for the periods in Article 10(1) of the Directive.2 The marketing authorisation holder is responsible for marketing the product, and appointing a representative does not displace that legal responsibility.2
A marketing authorisation under the Directive may only be granted to an applicant established in the Union.2 Article 8(2a) allows the competent authorities of the United Kingdom in respect of Northern Ireland to authorise applicants established in other parts of the United Kingdom. Under Article 8(2b) the competent authorities of Cyprus, Ireland and Malta could use the mutual recognition or decentralised procedure for holders established in parts of the United Kingdom other than Northern Ireland until 31 December 2024. Authorisations granted or extended by those three authorities on that basis cease to be valid at the latest on 31 December 2026.2
Compulsory and optional use of the centralised procedure
Article 3(1) of Regulation (EC) No 726/2004 makes the Union authorisation the only route for a product appearing in the Annex.1 Article 3(2) opens the procedure to a product outside Annex I in two situations. The first is a product containing an active substance that was not authorised in the Union on 20 May 2004. The second requires the applicant to show that the product is a significant therapeutic, scientific or technical innovation, or that authorisation by the Union serves patients’ health at Union level.1
Article 3(3) runs the other way for generics. A generic of a reference product authorised by the Union may be authorised by national competent authorities under the Directive where the application is made under Article 10 of the Directive. The summary of product characteristics must be consistent in all relevant respects with that of the centrally authorised product, except for parts referring to indications or dosage forms still covered by patent law when the generic was marketed. The generic must be authorised under the same name in every Member State where an application has been made, and all linguistic versions of the international non-proprietary name count as the same name.1
Time and procedure in the centralised route
The Committee for Medicinal Products for Human Use draws up the Agency opinion on admissibility of the file, on granting, variation, suspension and revocation, and on pharmacovigilance.1 The Agency must ensure that the opinion is given within 210 days of receipt of a valid application. Analysis of the scientific data must run for at least 80 days, unless the rapporteur and co-rapporteur declare their assessment complete earlier. The Committee may call for that analysis period to be extended on a duly reasoned request.1
An applicant who receives an opinion under Article 9(1) has 15 days from receipt of that opinion to notify the Agency of a request for re-examination, and 60 days from receipt of that opinion to supply the detailed grounds. The Committee re-examines within 60 days of receiving the grounds.1 The Agency sends the final opinion to the Commission, the Member States and the applicant within 15 days of its adoption, with an assessment report.1
The Commission prepares a draft decision within 15 days of receipt of the opinion.1 Member States have 22 days to submit written observations, shortened where a decision is urgent but normally never below 5 days. A Member State may ask in writing for plenary discussion in the Standing Committee on Medicinal Products for Human Use. Where written observations raise important new scientific or technical questions that the Agency opinion did not address, the Chairman suspends the procedure and refers the application back to the Agency. The Commission takes the final decision by implementing act within 15 days of obtaining the Standing Committee opinion.1
Article 14(9) provides an accelerated assessment for products of major interest from the point of view of public health, in particular therapeutic innovation. The request must be duly substantiated. Where the Committee accepts it, the 210-day limit falls to 150 days.1
Mutual recognition and the decentralised procedure
Article 28 of the Directive governs authorisation in more than one Member State on an identical dossier. The applicant names one Member State as reference Member State and lists the concerned Member States.2
Where the product already holds a marketing authorisation at the time of application, the concerned Member States recognise the authorisation granted by the reference Member State. The holder asks that State to prepare or update the assessment report, which it does within 90 days of a valid application.2 Where the product holds no authorisation at that point, the reference Member State prepares a draft assessment report, a draft summary of product characteristics and drafts of the labelling and package leaflet within 120 days of a valid application.2
The concerned Member States then have 90 days to approve those documents and inform the reference Member State, which records the agreement and closes the procedure. Each Member State adopts its national decision in conformity with the approved documents within 30 days of acknowledgement of the agreement.2 Where the evaluation in a mutual recognition procedure produces disagreement, the Committee for Medicinal Products for Human Use formulates an opinion, and that opinion is made publicly accessible.1
Evidence in a full application
A centralised application must include the particulars and documents referred to in Articles 8(3), 10, 10a, 10b or 11 of Directive 2001/83/EC and in Annex I to that Directive, with a statement that clinical trials conducted outside the European Union met the ethical requirements of Directive 2001/20/EC. A single name must be used for the product, other than in exceptional cases relating to trade mark law, and the application must be accompanied by the Agency fee.1
The particulars listed in Article 8(3) of the Directive include the following:
- the name or corporate name and permanent address of the applicant and, where applicable, of the manufacturer
- the name of the product and qualitative and quantitative particulars of all constituents, with the international non-proprietary name where one exists
- an evaluation of the potential environmental risks posed by the product, assessed case by case
- a description of the manufacturing method and of the control methods used by the manufacturer
- therapeutic indications, contra-indications and adverse reactions, together with posology and pharmaceutical form. The route of administration and expected shelf life are included.
- the results of pharmaceutical, pre-clinical and clinical tests and trials, with detailed summaries under Article 12
- written confirmation that the manufacturer of the product has audited the active substance manufacturer for compliance with good manufacturing practice, with the audit date and outcome
- a summary of the applicant’s pharmacovigilance system and the risk management plan with its summary
- the proposed summary of product characteristics, packaging mock-ups and package leaflet
- a document showing that the manufacturer is authorised to produce medicinal products in its own country
- copies of authorisations, proposed or approved product information, and refusal decisions from other Member States or third countries
- a copy of any orphan designation under Regulation (EC) No 141/2000 with the relevant Agency opinion.2
The risk management system must be proportionate to the identified and potential risks and to the need for post-authorisation safety data.2
A product containing or consisting of genetically modified organisms carries extra documents under Article 6(2) of the Regulation. These are the written consent to deliberate release for research and development where Part B of Directive 2001/18/EC applies, the complete technical dossier under Annexes III and IV to that Directive, the environmental risk assessment under its Annex II and the results of research or development investigations. Articles 13 to 24 of Directive 2001/18/EC do not apply to such medicinal products, and the Committee opinion must respect the environmental safety requirements of that Directive.1
Reduced evidence for generics, hybrids and similar biological products
Article 10(1) of the Directive relieves a generic applicant of pre-clinical and clinical results where the reference product is or has been authorised under Article 6 for not less than eight years in a Member State or the Union. The generic may not be placed on the market until ten years have elapsed from the initial authorisation of the reference product. That ten-year period extends to a maximum of eleven years where the holder obtains, within the first eight of those ten years, an authorisation for one or more new therapeutic indications held to bring significant clinical benefit over existing therapies.2
A generic medicinal product has the same qualitative and quantitative composition in active substances and the same pharmaceutical form as the reference product, with bioequivalence shown by appropriate bioavailability studies. The following different forms count as the same active substance unless they differ significantly in safety or efficacy properties.
- salts
- esters
- ethers
- isomers
- mixtures of isomers
- complexes
- derivatives
Immediate-release oral forms count as one pharmaceutical form. Bioavailability studies may be dispensed with where the applicant demonstrates that the product meets the criteria in the relevant detailed guidelines.2
Article 10(3) applies where the product falls outside the generic definition, where bioequivalence cannot be shown through bioavailability studies, or where the active substance, indications, strength, form or route differ from the reference product. Results of the appropriate pre-clinical tests or clinical trials must then be provided.2
Article 10(4) covers a biological medicinal product similar to a reference biological product that does not meet the generic definition, in particular because of differences in raw materials or in manufacturing processes. The applicant must provide the results of appropriate pre-clinical tests or clinical trials relating to those conditions. The type and quantity of supplementary data follow the criteria in Annex I and the related detailed guidelines. Other test and trial results from the reference product dossier are not provided.2
Article 10(5) grants a non-cumulative one-year period of data exclusivity for a new indication for a well-established substance, provided significant pre-clinical or clinical studies were carried out for that indication.2 Studies and trials conducted for the purposes of Article 10(1) to (4) are not contrary to patent rights or supplementary protection certificates.2
Authorisation before the data are complete
Two provisions of the Regulation allow a Union authorisation on less than a complete package. Article 14(8) permits authorisation subject to conditions in exceptional circumstances, following consultation with the applicant, where the applicant shows for objective and verifiable reasons that comprehensive efficacy and safety data under normal conditions of use cannot be provided. The grounds must be among those in Annex I to the Directive, and continuation depends on annual reassessment of the conditions.1
Article 14-a allows authorisation before comprehensive clinical data are submitted for products intended to treat, prevent or diagnose seriously debilitating or life-threatening diseases, where the benefit of immediate availability outweighs the risk of the missing data. In emergency situations the authorisation may be granted where comprehensive pre-clinical or pharmaceutical data have also not been supplied. The risk-benefit balance must be favourable and the applicant must be likely to be able to supply comprehensive data.1
An authorisation under Article 14-a carries specific obligations, reviewed annually by the Agency, and these include completing ongoing studies or conducting new ones to confirm the risk-benefit balance. The summary of product characteristics and the package leaflet must state clearly that the authorisation is subject to those obligations. It is valid for one year on a renewable basis. Once the specific obligations are fulfilled, the Commission may grant a five-year authorisation on application by the holder and after a favourable Agency opinion.1
Validity, renewal and lapse
A Union marketing authorisation is valid for five years.1 It may be renewed after five years on the basis of an Agency re-evaluation of the risk-benefit balance. The holder must supply a consolidated quality, safety and efficacy file at least 9 months before expiry, covering adverse reaction data, periodic safety update reports and all variations since grant. Once renewed the authorisation runs for an unlimited period, unless the Commission decides on justified pharmacovigilance grounds to require one further five-year renewal.1
An authorisation lapses if the product is not placed on the Union market in fact within three years of authorisation, or if an authorised product already on the market is absent from it for three consecutive years. The Commission may grant duly justified exemptions from both rules in exceptional circumstances and on public health grounds.1
Products authorised under the Regulation benefit from eight years of data protection and ten years of marketing protection. The marketing protection extends to a maximum of eleven years where the holder obtains, within the first eight of those ten years, an authorisation for one or more new therapeutic indications held during scientific evaluation to bring significant clinical benefit over existing therapies.1
Questions people also ask
Can a product outside the Annex to Regulation (EC) No 726/2004 use the centralised procedure?
Yes, on the grounds in Article 3(2). Either the product contains an active substance that was not authorised in the Union on 20 May 2004, or the applicant shows that the product is a significant therapeutic, scientific or technical innovation, or that authorisation by the Union is in the interest of patients’ health at Union level.1
How long does the centralised procedure take from valid application to Commission decision?
The Committee opinion is due within 210 days of a valid application, or 150 days where accelerated assessment is granted under Article 14(9).1 The Commission prepares a draft decision within 15 days of the opinion, Member States have 22 days for written observations, and the final implementing act follows within 15 days of the Standing Committee opinion.1
What separates mutual recognition from the decentralised procedure?
Both run under Article 28 of Directive 2001/83/EC on an identical dossier. Where the product already holds an authorisation, the reference Member State prepares or updates its assessment report within 90 days and the other Member States recognise its authorisation. Where no authorisation exists yet, the reference Member State produces draft documents within 120 days. Both paths then allow 90 days for approval by the concerned Member States and 30 days for national decisions.2
What evidence must a similar biological medicinal product provide?
Under Article 10(4) of the Directive, the applicant provides results of appropriate pre-clinical tests or clinical trials relating to differences from the reference biological product, such as differences in raw materials or manufacturing processes. The type and quantity of supplementary data follow Annex I and the related detailed guidelines. Other test and trial results from the reference dossier are not submitted.2
When does a marketing authorisation stop being valid without any regulatory action?
Article 14(4) and (5) of the Regulation end an authorisation that is not followed by actual placing on the Union market within three years of grant, and one where a product previously on the market has been absent for three consecutive years. The Commission may grant duly justified exemptions in exceptional circumstances on public health grounds.1
Footnotes
-
Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. Consolidated version of 2022-01-28. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:02004R0726-20220128 ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12 ↩13 ↩14 ↩15 ↩16 ↩17 ↩18 ↩19 ↩20 ↩21 ↩22 ↩23 ↩24 ↩25 ↩26
-
Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use. Consolidated version of 2025-01-01. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:02001L0083-20250101 ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12 ↩13 ↩14 ↩15 ↩16 ↩17 ↩18 ↩19 ↩20 ↩21
Pothos builds longitudinal molecular profiles of individuals: whole-genome sequencing, single-cell RNA sequencing, and plasma proteomics, delivered as a detailed report, every data file, and stored cells. Build your profile.